Skip to main
MYO

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo is benefiting from accelerating top-line momentum, with fiscal Q2 2026 revenue of $11.7 million, up 21% year over year and above both estimates and guidance, while EPS of $(0.09) also outperformed expectations. The fundamental outlook is strengthened by stronger unit sales, a lower reimbursement pipeline and manageable backlog that still supports future conversions, plus raised 2026 revenue guidance to $45 million to $47 million and Q3 guidance of $11.5 million to $12.0 million. Long-term growth is further supported by the March 2024 Medicare Part B ruling, which materially expands the reimbursable market for MyoPro and is driving rapid growth in U.S. O&P revenue, which rose 100% in 2025 and 130% in Q2.

Bears say

Myomo is facing a weakening liquidity profile, with cash declining to $14 million from $16 million at the end of March while debt rose to $12 million from $11 million, suggesting less financial flexibility. Its prior balance sheet also showed deterioration, with cash down to $16 million from $18 million at the end of December, reinforcing concerns that the company may need to fund operations and commercialization under tighter conditions. Beyond the balance sheet, the business remains exposed to reimbursement uncertainty, regulatory and commercialization risks, and shifting healthcare priorities, all of which could pressure execution and investor confidence.

Myomo (MYO) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Oct 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.